Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy.
THDBH120, which is being developed to treat type 2 diabetes (T2D), combines the proinsulin effects of GLP-1 and GIP into a single molecule and improves metabolic stability through molecular design, thereby enhancing blood glucose control. The study is designed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in T2D patients.- Flcube.com
